Fig 1: Reporter cytokine assays (JAK family). (a) Schematic representation of the JAK–STAT signaling pathways activated by TPO, IL-2, and IFN-α/β (Created in BioRender. Wass, B. [2026] https://BioRender.com/t4kx833). The TPO pathway signals through JAK2 homodimers, leading to STAT5 phosphorylation and downstream activation of the SEAP reporter gene via its promoter. The IL-2 pathway activates JAK1/JAK3 heterodimers, also resulting in STAT5 phosphorylation and SEAP expression. The IFN-α/β pathway signals through JAK1/TYK2 heterodimers, phosphorylating STAT1 and STAT2, which induce SEAP expression. This system illustrates the distinct JAK combinations involved in each cytokine pathway. (b) Dose–response curves demonstrate how five JAK inhibitors (povorcitinib, upadacitinib, abrocitinib, baricitinib, and tofacitinib) inhibit signaling via the JAK2/JAK2 (TPO), JAK1/JAK3 (IL-2), and JAK1/TYK2 (IFN-α) pathways. Pathway inhibition was quantified as the percentage of cytokine-induced signaling inhibition (y-axis), and compounds were tested at a variety of concentrations. IFN interferon, IL interleukin, JAK Janus kinase, SEAP secreted alkaline phosphatase, STAT signal transducer and activator of transcription, TPO thrombopoietin, TYK2 tyrosine kinase 2
Supplier Page from R&D Systems, a Bio-Techne Brand for Animal-Free™ IL-2 Protein
Available conjugates: Sizes Available: 50 ug (also 1 mg)